Figure 5.

Narciclasine improves the survival of mice bearing brain melanoma metastatic xenografts. A) Typical hematoxylin eosin staining of a tumor that developed in the brain of a nude mouse 1 mo after the stereotactical graft of human melanoma brain metastatic cells (×50). T, tumor; NB, normal brain tissue; black arrows indicate invasive islets). B) Kaplan-Meier survival analysis of the tumor-bearing mice left untreated, treated with narciclasine (1 mg/kg p.o.; 2 administrations/wk for 3 wk) or with temozolomide (TMZ, 40 mg/kg p.o.; 3 administrations/wk for 3 wk).